Form 8-K - Current report:
SEC Accession No. 0001564590-20-015274
Filing Date
2020-04-03
Accepted
2020-04-03 16:30:53
Documents
2
Period of Report
2020-03-31
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20200331.htm 8-K 38000
2 EX-3.1 agle-ex31_7.htm EX-3.1 249676
  Complete submission text file 0001564590-20-015274.txt   288844
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 20773806
SIC: 2834 Pharmaceutical Preparations